Metabolic and cardiovascular complications in HIV-infected patients: new challenges for a new age.
J. Infect. Dis., Jun;205 Suppl 3:S353-4 (2012)
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Lancet., Jun;379(9835):2439-48 (2012)
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
J. Infect. Dis., Oct;204(8):1191-201 (2011)
Projected survival gains from revising state laws requiring written opt-in consent for HIV testing.
J Gen Intern Med., Jun;26(6):661-7 (2011)
Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164.
HIV Clin Trials., 11(5):248-59 (2010)
The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort.
J. Viral Hepat., Jul;18(7):506-12 (2011)
Untreated HIV: harmful even at high CD4 cell counts.
Lancet., Jul;376(9738):306-8 (2010)
Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system.
J. Acquir. Immune Defic. Syndr., Dec;55(5):615-9 (2010)
Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents.
HIV Clin Trials., 10(1):13-24 (2009)
Antiretroviral therapy for treatment-naÃ¯ve patients: a review of recent literature and the updated guidelines.
Curr Infect Dis Rep., Jul;11(4):311-8 (2009)
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
N. Engl. J. Med., Dec;361(23):2230-40 (2009)
The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
AIDS., Oct;22(15):2025-33 (2008)
Strategies for management and treatment of dyslipidemia in HIV/AIDS.
AIDS Care., Feb;18(2):149-57 (2006)
The survival benefits of AIDS treatment in the United States.
J. Infect. Dis., Jul;194(1):11-9 (2006)
Evaluation and management of early virological failure.
Curr Opin HIV AIDS., Sep;1(5):409-16 (2006)
The lifetime cost of current human immunodeficiency virus care in the United States.
Med Care., Nov;44(11):990-7 (2006)
Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
Arthritis Rheum., Jun;56(6):1754-64 (2007)
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial.
Clin. Infect. Dis., Oct;45(8):1062-70 (2007)
Routine human immunodeficiency virus testing: an economic evaluation of current guidelines.
Am. J. Med., Mar;118(3):292-300 (2005)
Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies.
J. Infect. Dis., May;191(9):1435-41 (2005)